A Study of LY3202626 in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-15

Study Completion Date

2017-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purposes of this study are to determine:

* If there are any differences in the way LY3202626 is handled by the body when taken in two different forms
* Whether a high fat meal affects the way the body handles LY3202626
* How well tolerated LY3202626 is

There are three (3) study periods for all participants. Participants will be admitted to the clinical research unit (CRU) each period and will be discharged from the CRU following the completion of 2 overnight stays and up to 36 hours after dosing with LY3202626.

The study will last about 50 days, not including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3023414 Formulations and the Effect of Food

NCT02818335

Healthy

COMPLETED PHASE1

A Study to Compare Two Forms of LY2608204 in Healthy People

NCT01313286

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3337641 in Healthy Participants

NCT03099148

Healthy

COMPLETED PHASE1

A Study of LY2409021 Formulations and the Effect of Food

NCT01354496

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3866288 in Healthy Participants

NCT06641037

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3202626 (R-Fasting)

Single oral dose of LY3202626 (R) capsule under fasting conditions.

Group Type EXPERIMENTAL

LY3202626 (R-Fasting)

Intervention Type DRUG

Administered orally

LY3202626 (T1-Fasting)

Single oral dose of LY3202626 (T1) tablet under fasting conditions.

Group Type EXPERIMENTAL

LY3202626 (T1-Fasting)

Intervention Type DRUG

Administered orally

LY3202626 (T1-Fed)

Single oral dose of LY3202626 (T1) following a high fat breakfast.

Group Type EXPERIMENTAL

LY3202626 (T1-Fed)

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3202626 (R-Fasting)

Administered orally

Intervention Type DRUG

LY3202626 (T1-Fasting)

Administered orally

Intervention Type DRUG

LY3202626 (T1-Fed)

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are overtly healthy males or females, as determined by medical history and physical examination
* Female participants must be of non-childbearing potential confirmed by medical history or menopause
* Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m²) inclusive, at screening

Exclusion Criteria

* Are investigative site personnel directly affiliated with this study and their immediate families
* Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
* Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
* Have previously completed or withdrawn from this study or any other study investigating LY3202626, and have previously received the investigational product
* Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
* Have a history of head trauma with loss of consciousness within the last 5 years
* Have known or ongoing psychiatric disorders

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes